Sarah M Moran1,2, Jennifer Scott1, Michael R Clarkson3, Niall Conlon4, Jean Dunne4, Matthew D Griffin5,6, Tomas P Griffin5,7, Elizabeth Groarke4, John Holian8, Conor Judge6,7, Jason Wyse9, Kirsty McLoughlin4, Paul V O'Hara10, Mark A Little11,10,12, Matthias Kretzler13,14. 1. Trinity Health Kidney Centre, Trinity College Dublin, Dublin, Ireland. 2. Department of Medicine, Queen's University, Kingston, Ontario, Canada. 3. Cork University Hospital, Ireland, University College Cork, Cork, Ireland. 4. St James's Hospital, Dublin, Ireland. 5. REMEDI at CÚRAM SFI Centre for Research in Medical Devices, School of Medicine, National University of Ireland, Galway, Ireland. 6. Department of Nephrology, Saolta University Health Care Group, Galway University Hospitals, Galway, Ireland. 7. Centre for Endocrinology, Diabetes and Metabolism, Saolta University Health Care Group, Galway University Hospitals, Galway, Ireland. 8. St Vincent's University Hospital, Dublin, Ireland. 9. Discipline of Statistics and Information Systems, Trinity College Dublin, Dublin, Ireland. 10. Beaumont Kidney Centre, Dublin, Ireland. 11. Trinity Health Kidney Centre, Trinity College Dublin, Dublin, Ireland mlittle@tcd.ie. 12. Tallaght University Hospital, Dublin, Ireland. 13. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 14. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Up to 70% of patients with ANCA-associated vasculitis (AAV) develop GN, with 26% progressing to ESKD. Diagnostic-grade and noninvasive tools to detect active renal inflammation are needed. Urinary soluble CD163 (usCD163) is a promising biomarker of active renal vasculitis, but a diagnostic-grade assay, assessment of its utility in prospective diagnosis of renal vasculitis flares, and evaluation of its utility in proteinuric states are needed. METHODS: We assessed a diagnostic-grade usCD163 assay in (1) a real-world cohort of 405 patients with AAV and 121 healthy and 488 non-AAV disease controls; (2) a prospective multicenter study of 84 patients with potential renal vasculitis flare; (3) a longitudinal multicenter cohort of 65 patients with podocytopathy; and (4) a cohort of 29 patients with AAV (with or without proteinuria) and ten controls. RESULTS: We established a diagnostic reference range, with a cutoff of 250 ng/mmol for active renal vasculitis (area under the curve [AUC], 0.978). Using this cutoff, usCD163 was elevated in renal vasculitis flare (AUC, 0.95) but remained low in flare mimics, such as nonvasculitic AKI. usCD163's specificity declined in patients with AAV who had nephrotic-range proteinuria and in those with primary podocytopathy, with 62% of patients with nephrotic syndrome displaying a "positive" usCD163. In patients with AAV and significant proteinuria, usCD163 normalization to total urine protein rather than creatinine provided the greatest clinical utility for diagnosing active renal vasculitis. CONCLUSIONS: usCD163 is elevated in renal vasculitis flare and remains low in flare mimics. Nonspecific protein leakage in nephrotic syndrome elevates usCD163 in the absence of glomerular macrophage infiltration, resulting in false-positive results; this can be corrected with urine protein normalization.
BACKGROUND: Up to 70% of patients with ANCA-associated vasculitis (AAV) develop GN, with 26% progressing to ESKD. Diagnostic-grade and noninvasive tools to detect active renal inflammation are needed. Urinary soluble CD163 (usCD163) is a promising biomarker of active renal vasculitis, but a diagnostic-grade assay, assessment of its utility in prospective diagnosis of renal vasculitis flares, and evaluation of its utility in proteinuric states are needed. METHODS: We assessed a diagnostic-grade usCD163 assay in (1) a real-world cohort of 405 patients with AAV and 121 healthy and 488 non-AAV disease controls; (2) a prospective multicenter study of 84 patients with potential renal vasculitis flare; (3) a longitudinal multicenter cohort of 65 patients with podocytopathy; and (4) a cohort of 29 patients with AAV (with or without proteinuria) and ten controls. RESULTS: We established a diagnostic reference range, with a cutoff of 250 ng/mmol for active renal vasculitis (area under the curve [AUC], 0.978). Using this cutoff, usCD163 was elevated in renal vasculitis flare (AUC, 0.95) but remained low in flare mimics, such as nonvasculitic AKI. usCD163's specificity declined in patients with AAV who had nephrotic-range proteinuria and in those with primary podocytopathy, with 62% of patients with nephrotic syndrome displaying a "positive" usCD163. In patients with AAV and significant proteinuria, usCD163 normalization to total urine protein rather than creatinine provided the greatest clinical utility for diagnosing active renal vasculitis. CONCLUSIONS: usCD163 is elevated in renal vasculitis flare and remains low in flare mimics. Nonspecific protein leakage in nephrotic syndrome elevates usCD163 in the absence of glomerular macrophage infiltration, resulting in false-positive results; this can be corrected with urine protein normalization.
Authors: Herbert A Hauer; Ingeborg M Bajema; Hans C van Houwelingen; Franco Ferrario; Laure-Hélène Noël; Rüdiger Waldherr; David R W Jayne; Niels Rasmussen; Jan A Bruijn; E Christiaan Hagen Journal: Kidney Int Date: 2002-01 Impact factor: 10.612
Authors: Eva M Weissinger; Stefan Wittke; Thorsten Kaiser; Hermann Haller; Sebastian Bartel; Ronald Krebs; Igor Golovko; Harald D Rupprecht; Marion Haubitz; Hartmut Hecker; Harald Mischak; Danilo Fliser Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: Siobhan M Hamon; Tomás P Griffin; Md Nahidul Islam; Deirdre Wall; Matthew D Griffin; Paula M O'Shea Journal: Clin Chem Lab Med Date: 2019-03-26 Impact factor: 3.694
Authors: Babs O Fabriek; Robin van Bruggen; Dong Mei Deng; Antoon J M Ligtenberg; Kamran Nazmi; Karin Schornagel; Rianka P M Vloet; Christine D Dijkstra; Timo K van den Berg Journal: Blood Date: 2008-10-10 Impact factor: 22.113
Authors: Emilio D Poggio; Robyn L McClelland; Kristina N Blank; Spencer Hansen; Shweta Bansal; Andrew S Bomback; Pietro A Canetta; Pascale Khairallah; Krzysztof Kiryluk; Stewart H Lecker; Gearoid M McMahon; Paul M Palevsky; Samir Parikh; Sylvia E Rosas; Katherine Tuttle; Miguel A Vazquez; Anitha Vijayan; Brad H Rovin Journal: Clin J Am Soc Nephrol Date: 2020-10-15 Impact factor: 8.237
Authors: Hanni Menn-Josephy; Carol S Lee; Angela Nolin; Marta Christov; Denis V Rybin; Janice M Weinberg; Joel Henderson; Ramon Bonegio; Andrea Havasi Journal: Am J Nephrol Date: 2016-09-15 Impact factor: 3.754
Authors: Rennie L Rhee; John C Davis; Linna Ding; Fernando C Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; W Joseph McCune; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; John H Stone; Peter A Merkel Journal: Clin J Am Soc Nephrol Date: 2018-01-25 Impact factor: 8.237
Authors: Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant Journal: N Engl J Med Date: 2009-07-02 Impact factor: 91.245
Authors: Md Nahidul Islam; Tomás P Griffin; Robert Whiriskey; Siobhan Hamon; Brendan Cleary; Liam Blake; Damian G Griffin; Matthew D Griffin; Janusz Krawczyk; Paula M O'Shea Journal: Ir J Med Sci Date: 2021-02-11 Impact factor: 1.568